Company profilePharmaceutical#463 of 1,318 in Pakistan✓ No DRAP alerts

STANDARD DRUG CO.

Pharmaceutical company · 32 brands · 35 molecules

32 registered products 16 pharmaceutical brands 35 distinct molecules 0 DRAP alerts

Company overview

32
registered products
16
pharmaceutical brands
35
distinct molecules
0
therapeutic classes
0
DRAP alerts

STANDARD DRUG CO. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 32 product registrations across 35 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Paracetamol2 brands
Diclofenac2 brands
Isoniazid2 brands
Artemether1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official1 products · Rs 141.2 – Rs 141.2
Median across source: Rs 141.2

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Albro Pharmaceuticals16 shared molecules
SEARLE PAKISTAN (PVT.) LTD.14 shared molecules
IRZA PHARMA (PVT) LTD.14 shared molecules
SYNTEX PHARMACEUTICALS14 shared molecules
REGENT LABORATORIES LTD.13 shared molecules

Get the full profile for STANDARD

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.